CytoSorbents Corporation (CTSO)

[andy55q]

The Netherlands Journal of Critical Care (NJCC)

Case Reports
G.W. van der Linde, A.F. Grootendorst

Septic shock is one of the greatest challenges in intensive care medicine. Despite the development of several new therapies, morbidity and mortality remain high. The so-called holy grail has yet to be found. High-volume continuous renal replacement therapy has been subject to research for some time, with limited success. One of the novel therapies on septic shock is haemoadsorption with a CytoSorb® adsorber. We present the case of an adolescent with Staphylococcus aureus toxic shock syndrome treated with the CytoSorb® adsorber, who made a remarkable recovery afterwards. To the best of our knowledge, this was the first application of the CytoSorb® adsorber in the Netherlands. The effects of haemoadsorption with CytoSorb® have been investigated mainly in animal experimental studies; to date, there is very limited data on the use in human septic shock.

http://njcc.nl/sites/default/files/pdf/case-report4_0.pdf